Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic
  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

ProMIS Neurosciences (NASDAQ: PMN) Unveils Potential Therapeutic Advantage of PMN310 in Alzheimer’s Disease

Rationally Designed PMN310 Targets Toxic Amyloid-Beta Oligomers Selectively and Efficiently

ProMIS Neurosciences, a pioneering biotech firm specializing in antibody therapeutics targeting toxic misfolded proteins linked to neurodegenerative conditions such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA), showcased new preclinical data at the Alzheimer’s Association International Conference (AAIC) 2023. This data emphasizes the potential benefits of their leading AD candidate, PMN310.

PMN310’s Selective Action on Amyloid-Beta Oligomers

The highlighted findings revealed that PMN310 could more selectively target toxic amyloid-beta oligomers compared to other amyloid-beta-oriented antibodies synthesized using synthetic oligomers. PMN310 is a humanized IgG1 antibody, focusing on these toxic amyloid-beta oligomers (AβO).

ProMIS’s proprietary computational modeling platform generated PMN310, using an algorithm to identify specific targets in a toxic protein species to avoid cross-reactivity with other protein forms. Such a highly selective AβO-targeted response potentially leads to enhanced clinical activity and improved safety profile, outpacing less selective approaches.

A Milestone for ProMIS – FDA Approval and Phase 1a Clinical Trial

In May 2023, the U.S. Food and Drug Administration (FDA) approved ProMIS’s Investigational New Drug (IND) application for PMN310 for AD treatment. Following this clearance, the company plans to launch a Phase 1a clinical trial to assess the pharmacokinetics, safety, and tolerability of PMN310 in healthy adult volunteers.

Vaccine Candidate for Alzheimer’s Disease Prevention

ProMIS is also making strides in preventative measures for AD. Their rationally designed vaccine candidate has shown a robust and sustained antibody response in preclinical evaluations. This response is primarily focused on pathogenic amyloid-beta oligomers, which further supports the company’s efforts to generate a highly selective AβO-targeted response.

Achieving Potent AD Prevention

The vaccine consists of an AβO conformational B cell peptide epitope linked to a carrier protein to provide T cell help. This combination has elicited a robust and enduring antibody response. Moreover, the serum antibodies were selective for AβO with no detectable binding to monomers or plaque, reducing the risk of Aβ-related imaging abnormalities (ARIA). This promising data backs ProMIS’s approach in designing an AD prevention vaccine that offers sustained anti-disease activity with fewer doses compared to chronic antibody treatment.

With the advancements of PMN310 and the AD prevention vaccine, ProMIS Neurosciences is poised to revolutionize the fight against Alzheimer’s disease. By leveraging computational modeling platforms and focusing on highly selective AβO-targeted responses, the company is setting new benchmarks in neurodegenerative disease research and therapy.

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post ProMIS Neurosciences (NASDAQ: PMN) Unveils Potential Therapeutic Advantage of PMN310 in Alzheimer’s Disease appeared first on Spotlight Growth.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.